Visit Website →
← Back to blog

FDA Shortage Ended: Semaglutide Compounding Rules and COA Checks

September 27, 2026
FDA Shortage Ended: Semaglutide Compounding Rules and COA Checks

Compounded semaglutide is legal in the United States only under narrow, patient-specific conditions defined by 503A and 503B of the FD&C Act, and those conditions have tightened sharply since the FDA declared the national shortage resolved. Mass-produced compounded versions marketed as generic alternatives to Ozempic or Wegovy fall outside the law in nearly every case now that shortage-based exemptions no longer apply. Clinicians and pharmacists who still compound semaglutide need to document a genuine, individualized medical reason and follow the compliance checklist detailed below.

TL;DR:

  • Mass compounding of semaglutide is now mostly illegal unless a patient-specific, documented medical reason justifies it, due to the end of shortage exemptions.
  • The FDA's proposed exclusion from the 503B Bulks List would further prohibit outsourcing facilities from bulk compounding semaglutide, tightening supply chain controls.
  • Compounded semaglutide carries significant safety risks, including unapproved formulations, mislabeled APIs, and lack of FDA safety review, causing documented adverse events.
  • Prescribers must ensure strict documentation of clinical necessity, source only verified APIs, and demand full quality certifications to stay within legal boundaries.
  • Verifying supplier claims through accredited lab tests and Certificates of Analysis is essential, as unverified or outdated documentation increases the risk of unsafe or non-compliant products.
USAPeptide
Verify Peptide Quality With Confidence
Access molecular data, research summaries, Certificates of Analysis, and tools designed to support careful peptide verification.
Explore peptide resources

Table of Contents

Compounded Semaglutide Legality: The Timeline That Changed Everything

The legal window for mass compounding of semaglutide opened during the 2022 to 2024 shortage and has been closing steadily since. Once the FDA confirms a drug is no longer in shortage, the special allowances that let 503A and 503B pharmacies replicate a commercially available product disappear almost immediately.

The FDA declared the semaglutide and tirzepatide shortages resolved, cutting off the primary legal justification compounders had relied on for two years. Then, in a move that would functionally end large-scale outsourcing-facility production of these drugs, the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment period on that proposal closed June 29, 2026.

Key milestones shaping legality right now:

  • Shortage resolution ended blanket compounding allowances for both semaglutide and tirzepatide.
  • The proposed 503B Bulks List exclusion would bar outsourcing facilities from compounding these APIs in bulk, even with a prescription on file.
  • FDA revised Import Alert 1186 to detain active pharmaceutical ingredient shipments from unverified foreign manufacturers, tightening the supply chain compounders depend on.

How 503A and 503B Rules Govern Semaglutide Compounding

Two very different legal pathways exist, and confusing them is one of the fastest ways a pharmacy ends up in enforcement crosshairs.

  1. 503A pharmacies compound for an individual, named patient based on a valid prescription. They are exempt from federal cGMP requirements but must operate within state board of pharmacy rules and cannot mass-produce for stock.
  2. 503B outsourcing facilities register with the FDA, follow current good manufacturing practice standards, and can compound in larger batches, but only using APIs approved for the Bulks List. The pending exclusion of semaglutide from that list would remove this pathway for GLP-1 drugs almost entirely.
  3. "Essentially a copy" test. The FDA treats a compounded product as an unlawful copy when it shares the same active ingredient, strength, and route of administration as a commercially available drug, unless a documented clinical difference justifies it, a standard the agency clarified as national supply stabilized.
  4. Small-volume exception. Some limited compounding, often cited around four or fewer prescriptions per month for a given formulation, may fall outside the "copy" prohibition if genuinely patient-specific.

A documented "significant difference" means something concrete: an allergy to an excipient in the FDA-approved product, a dosage strength the manufacturer doesn't produce, or a delivery method a patient's condition requires. A generic note like "patient prefers compounded" won't hold up under scrutiny.

What the Safety Data Says About Compounded Semaglutide

Compounded semaglutide has never gone through FDA premarket review for safety, effectiveness, or manufacturing quality, and that gap shows up in real patient harm. The agency has documented dosing errors and adverse events tied directly to compounded injectable GLP-1 products, some severe enough to require emergency care.

The problems cluster around a few recurring failure points:

  • Unapproved salt forms, such as semaglutide sodium, that the FDA has no equivalence data for and views with real skepticism.
  • Sublingual drops and dissolvable tablets marketed as convenient alternatives, despite having no human clinical data behind them.
  • Adulterated or mislabeled APIs that deliver the wrong dose entirely, sometimes far higher than intended.
  • Impurities introduced during compounding that wouldn't survive the quality checks a commercial manufacturer runs.

Statistic Callout: FDA inspections of API supply sites feeding the compounding market found a meaningful share of facilities out of compliance, a major reason the agency expanded Import Alert 1186 to detain shipments at the border rather than test them after entry.

Clinical commentary from Stanford Medicine points to another quiet risk: because 503A pharmacies aren't federally required to submit adverse event reports, the true rate of harm from compounded semaglutide is likely underreported.

FDA enforcement against illegitimate compounded GLP-1 sellers has shifted from occasional warning letters to active online monitoring, import detentions, and coordinated telehealth scrutiny. The agency has specifically flagged telehealth companies and pharmacies that market compounded products as "generic" or "clinically proven" equivalents to Ozempic or Wegovy, language that misrepresents a product with no FDA approval behind it.

Investigators increasingly treat certain patterns as evidence of mass production disguised as individualized care, including verbatim prescriber rationales repeated across thousands of orders.

Watch for these red flags before trusting a compounded semaglutide source:

  • Marketing that calls the product "generic semaglutide" or "the same as brand name."
  • Prescriber documentation that reads identically across many patients.
  • Packaging in a foreign language, damaged seals, or no batch number at all.
  • Missing or unverifiable Certificates of Analysis.
  • Delivery forms, like dissolvable strips, with no published clinical backing.

Pro Tip: If a supplier can't produce a current Certificate of Analysis showing ISO 17025-accredited testing and HPLC purity results within minutes of asking, treat that as a hard stop, not a delay.

A Compliance Checklist for Prescribers and Pharmacies

Staying inside the legal boundary starts with documentation that would survive an FDA audit, not just a chart note.

  1. Establish medical necessity in writing. Record the specific clinical reason, an allergy, a required strength the manufacturer doesn't make, or a delivery need, rather than patient preference alone.
  2. Keep volume patient-specific. Dispense in small, individualized quantities tied to an active prescription, not batch stock.
  3. Source only from verified suppliers. Prefer 503B-registered outsourcing facilities where the pathway still applies, and confirm any API against the FDA's Green List before purchase.
  4. Demand full COA documentation. Require ISO 17025-accredited lab results with HPLC purity data before accepting any shipment.
  5. Monitor patients closely. Schedule early follow-up visits after starting a compounded product, and report adverse events through MedWatch promptly, since 503A pharmacies aren't required to do so themselves.

Pro Tip: Build adverse-event reporting into your standard visit template for any patient on a compounded GLP-1. If reporting isn't routine, it tends not to happen at all.

Using Research Verification Tools Before You Trust a Supplier

Abstract supplier verification checkpoints

Verifying a Certificate of Analysis by eye is unreliable. USAPeptide's semaglutide reference page documents the molecular profile and regulatory distinctions between commercial and compounded versions, giving researchers a baseline to compare supplier claims against.

A COA grading tool assesses whether a submitted certificate shows genuine third-party testing markers or signs of fabrication, while peptide database and dosage calculator tools support research-dosing calculations rather than clinical prescribing. Useful checkpoints when evaluating any supplier:

  • Does the COA name an ISO 17025-accredited lab, and can that accreditation be independently verified?
  • Are HPLC purity results reported at or above 99%, with a clear methodology?
  • Does the batch number on the COA match the batch number on the product itself?

These tools support research verification and supply chain due diligence. They do not substitute for FDA approval, clinical quality systems, or a pharmacist's own compliance judgment.

Where the Law Should Bend, and Where It Shouldn't

FDA-approved semaglutide products remain the safer default whenever access allows it, and no compounded alternative changes that calculus. Where compounding is genuinely necessary, the documentation burden is not optional paperwork. It's the entire legal basis for the exception.

Clinicians who compound casually, without a real clinical rationale, small volumes, and verified sourcing, are exposed to enforcement risk that has only grown sharper through 2026. Reporting adverse events matters too, since underreporting from 503A settings hides the true safety picture.

— USAPeptide Team

Where to Verify Peptide Quality Before You Rely on It

If you're evaluating semaglutide or related metabolic peptides for research purposes, the biggest risk isn't the chemistry. It's trusting a Certificate of Analysis you can't actually verify.

USAPeptide

USAPeptide.info gives researchers and laboratories a way to check supplier claims against real standards, ISO 17025-accredited lab testing and HPLC purity data, rather than taking a vendor's word for it. The semaglutide research page breaks down mechanism and trial-design context that helps distinguish genuine chemical equivalence from marketing language. For a broader view of metabolic and GLP-1 related research compounds, the fat loss research guide organizes options by category rather than brand claims. This is research support and reference material, not clinical compounding supply or dosing advice. Start by running any supplier's COA through the grading tool on Usapeptide before you commit to a purchase.

Sources

For direct verification, go straight to the primary documents rather than secondhand summaries:

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

Compounded tirzepatide faces the same restrictions as semaglutide now that the FDA has declared its shortage resolved and proposed excluding it from the 503B Bulks List. Patient-specific 503A compounding with documented medical necessity remains the only viable path.

Are compounded GLP-1s going away?

Mass compounding of GLP-1 drugs like semaglutide and tirzepatide is shrinking fast as shortage-based exemptions expire and the proposed Bulks List exclusion moves forward. Narrow, individualized 503A compounding with proper documentation will likely persist, but large-scale outsourcing production is on track to end for these APIs.

Is Ozempic going to be covered by Medicare in 2026?

Medicare coverage for approved GLP-1 drugs expanded through the CMS GLP-1 Bridge demonstration, effective July 1, 2026, which opened certain coverage pathways for eligible beneficiaries outside standard Part D rules. Coverage still depends on individual plan design and medical criteria, so patients should confirm eligibility with their specific plan.

Can my doctor write a prescription for compounded semaglutide?

A doctor can prescribe compounded semaglutide only when there's a documented, patient-specific medical reason, such as an allergy to an excipient in the FDA-approved version or a needed strength the manufacturer doesn't produce. Preference alone, or simply wanting a lower price, doesn't meet the legal bar the FDA has set for compounders.